PMID- 22777298
OWN - NLM
STAT- MEDLINE
DCOM- 20121018
LR  - 20120726
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 83
IP  - 2
DP  - 2012
TI  - Relationship between immunological parameters and the severity of neutropenia and 
      effect of enteral nutrition on immune status during neoadjuvant chemotherapy on 
      patients with advanced esophageal cancer.
PG  - 91-100
LID - 10.1159/000339694 [doi]
AB  - OBJECTIVES: Chemotherapy may cause various toxicities as well as impair 
      immunological function. However, little is known about the relationship between 
      toxicities and immunological parameters or the effect of enteral nutrition (EN) 
      on immunological status during chemotherapy. METHODS: 91 patients who received 
      neoadjuvant chemotherapy (NACT) for esophageal cancer were randomly assigned to 
      receive either EN or parenteral nutrition (PN). Immunological parameters, 
      including total lymphocyte count (TLC), type 1 and type 2 CD4-positive T cells 
      (Th1/Th2) balance, human leukocyte antigen (HLA)-DR expression on monocytes, 
      natural killer cell activity, and phytohemagglutinin-stimulated lymphocyte 
      proliferation were measured at baseline and day 14 of the first chemotherapy 
      cycle. RESULTS: In the PN group, patients with grade 3-4 neutropenia showed 
      significantly lower TLC, HLA-DR expression, and Th1/Th2 balance at day 14 
      compared to those with grade 0-2 neutropenia. Among pretherapeutic factors, 
      Th1/Th2 balance was the only factor significantly associated with the severity of 
      neutropenia. Concerning the comparison of immunological parameters between the EN 
      and PN groups, HLA-DR expression at day 14 was significantly higher in the EN 
      group. CONCLUSIONS: Baseline Th1/Th2 balance predicted the severity of 
      neutropenia, and EN significantly reduced the decline of monocyte HLA-DR 
      expression in patients with esophageal cancer receiving NACT.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Motoori, Masaaki
AU  - Motoori M
AD  - Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Higashinari-ku, Osaka, Japan. motoori-ma@mc.pref.osaka.jp
FAU - Yano, Masahiko
AU  - Yano M
FAU - Yasuda, Takushi
AU  - Yasuda T
FAU - Miyata, Hiroshi
AU  - Miyata H
FAU - Peng, Ying Feng
AU  - Peng YF
FAU - Yamasaki, Makoto
AU  - Yamasaki M
FAU - Shiraishi, Osamu
AU  - Shiraishi O
FAU - Tanaka, Koji
AU  - Tanaka K
FAU - Ishikawa, Osamu
AU  - Ishikawa O
FAU - Shiozaki, Hitoshi
AU  - Shiozaki H
FAU - Doki, Yuichiro
AU  - Doki Y
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120709
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (HLA-DR Antigens)
SB  - IM
MH  - *Enteral Nutrition
MH  - Esophageal Neoplasms/*drug therapy/*immunology
MH  - Female
MH  - HLA-DR Antigens/immunology
MH  - Humans
MH  - Lymphocyte Count
MH  - Male
MH  - Middle Aged
MH  - Monocytes/drug effects/immunology
MH  - Multivariate Analysis
MH  - Neoadjuvant Therapy
MH  - Neutropenia/*immunology
MH  - Th1 Cells/drug effects/immunology
MH  - Th2 Cells/drug effects/immunology
EDAT- 2012/07/11 06:00
MHDA- 2012/10/19 06:00
CRDT- 2012/07/11 06:00
PHST- 2012/02/20 00:00 [received]
PHST- 2012/05/23 00:00 [accepted]
PHST- 2012/07/11 06:00 [entrez]
PHST- 2012/07/11 06:00 [pubmed]
PHST- 2012/10/19 06:00 [medline]
AID - 000339694 [pii]
AID - 10.1159/000339694 [doi]
PST - ppublish
SO  - Oncology. 2012;83(2):91-100. doi: 10.1159/000339694. Epub 2012 Jul 9.